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Abstract 
Objective: Associations between antipsychotic agent (AP) use and myocardial 
infarction (MI) risk have been inconsistent and remain controversial. We therefore 
conducted a meta-analysis of observational studies to address this knowledge gap. 
Method: Detailed electronic database searches were performed to identify reports of 
observational studies that evaluated the association between AP use and the risk of MI. 
Pooled odds ratios were calculated using random or fixed-effects models. 
Results: In total, 4 case-control studies, 2 case-crossover studies, 1 case-case time 
control study, 3 cohort studies, and 1 self-controlled case serieswere included. The 
pooled odds ratio (95% CIs) between any AP use and MI risk was 1.55 (1.33-1.79) 
compared with non-use: 1.39 (1.06-1.82) for atypical AP use and 1.57 (1.29-1.91) for 
typical AP use. Subgroup analyses indicated that male gender, schizophrenia 
diagnosis and AP exposure periods ≦60 days, but not prior cardiovascular disease 
diagnosisor older age, were associated with higher risk of MI. 
Conclusion: Current evidence, based on 10 observational studies, suggested that AP 
use might be a potential risk factor of MI. However, we cannot conclude at this time 
due to significant heterogeneity among studies. We suggest that, instead of not using 
APs in fear of the risk, careful cardiovascular monitoring before and during AP 
treatment in high-risk patients group is needed. Additional high-quality prospective 
studies are required to evaluate the association between APs and the risk of MI. 
 
Keywords 
Antipsychotic agents, myocardial infarction, meta-analysis, schizophrenia, serious 
mental illness 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Antipsychotic agents (APs) are first-line medication treatment for schizophrenia. 
They effectively reduce symptoms and behaviors associated with the disorder. In an 
11-year follow up study of schizophrenia patients, long term exposure (7-11 years) to 
AP treatment was associated with around a 20% lower mortality than those without 
medication use (Tiihonen et al., 2009). The use of APs is widespread, but 
accumulating data started to indicate  that these agents might correlate with 
cardiovascular risk.(Ray et al., 2009; Enger et al., 2004). The mechanism for this 
effect has yet to be fully clarified. APs may induce glucose or metabolic dysfunctions 
(Deng, 2013), QT interval prolongation, ventricular arrhythmia (Polcwiartek et al., 
2016), ischemic stroke (Sacchetti et al., 2010) and thereby increase cardiovascular 
risk (Scigliano and Ronchetti, 2013). However, the evidence for increased MI risk 
associated with the use of APs is conflicting. Some studies have reported an increased 
risk of MI associated with APs (Pratt et al., 1996; Thorogood et al., 1992; Enger et al., 
2004), whereas others have found no such association (Jerrell and McIntyre, 2007; 
Nakagawa et al., 2006). Methodological limitations and heterogeneous clinical 
settings have hindered conclusive findings (Brauer et al., 2011). Thus, further studies 
are needed to examine the associations. 
  Few meta-analyses have been conducted examining the risk of MI associated with 
the use of APs. A meta-analysis of observational studies found that older patients (> 
80 years) using typical APs were at higher risk for MI [relative risk (RR) = 1.2, 95% 
CIs: 1.16-1.23] compared to atypical AP users (Jackson et al., 2014);however, this 
only identified two cohort studies. Another meta-analysis found a 1.88-fold higher 
likelihood [odds ratio (OR) = 1.88, 95% CIs: 1.39-2.54) of MI in AP users vs. 
non-users (Yu et al., 2016). More pronounced MI risk (OR 2.64, 95% CIs 2.48-2.81) 
was found in short-term users. Among, the nine studies they identified, only two 
(Brauer et al., 2015; Pariente et al., 2012) provided separate estimates for different 
time windows after AP initiation. Besides, a more recently published study (Hwang et 
al., 2014) was not included in their meta- analysis. It is widely recognized that 
systematic reviews of randomized controlled trials (RCTs) represent the most reliable 
and appropriate reference standard to address questions of effectiveness, as they are 
designed to minimize bias. But for rare and adverse events, such as MI, systematic 
reviews of observational studies are the main source of evidence because RCTs tend 
to have insufficient sample size (even when combined) and generalizability to 
real-world practice. As there have been no RCTs investigating the occurrence of MI 
when taking APs, we performed a comprehensive meta-analysis of all observational 
studies to date to address this knowledge gap. 
 
Methods 
This review was reported according to PRISMA guidelines (Moher et al., 2009). 
 
Search strategy 
 
The eight databases searched for this study comprised Medline (Ovid), EMBASE, 
CENTRAL, PsycINFO, Psychology and Behavioral Sciences Collection (PBSC), 
CINAHL, Iowa Drug Information Service (IDIS), and Index to Taiwan Periodical 
Literature System (all from inception to the end of June 2016), and a supplementary 
search in TRIP Database and Google Scholar. References provided in the selected 
studies and systematic reviews were further checked for additional citations of 
published or unpublished reports. E-mail alerts were established to identify newly 
released studies from the databases that fell within the scope of our review. 
The keywords used in the search were antipsychotic agents and myocardial 
infarction. The search strategy included free-text and controlled vocabulary terms (e.g. 
Medical Subject Headings) for these topics. No language restrictions were applied. 
On the basis of the MEDLINE (Ovid) search strategy, queries were revised to perform 
the best searches in the other databases. The MEDLINE (Ovid) search strategy is 
shown in Table S2. 
 
Eligibility criteria 
 
We included studies that met all of the following criteria: (1) observational design (eg. 
case-control or cohort studies); (2) evaluation of the association between AP use and 
the risk of myocardial infarction (MI); (3) comparing APs to a non-user reference 
group; (4) direct reporting of RR, OR, or hazard ratio (HR) with corresponding 95% 
CIs; (5) using statistical adjustments for potential confounders. We excluded studies 
evaluated patients with dementia due to unlicensed indication. 
  Two authors (KLH and CCH) independently selected the trials based on the above 
criteria, and disagreements were resolved by a third author (SIW). Included studies 
were then assessed for quality using the nine-star Newcastle-Ottawa Scale 
(NOS)(Wells et al., 2008). The rating was also performed by two evaluators, and 
discrepancies were resolved by a third evaluator, as was study selection. Low quality 
was defined as an NOS score below the average value for the included studies, and 
high quality as an NOS score at or above the average. 
 
Data extraction 
 KLH and CCH extracted the data independently, with disagreements resolved through 
discussion and consensus with other team members. For each trial, data related to the 
characteristics of the trial and the reported results were extracted. The following data 
were collected: study name, study design, country, study period, characteristics of 
study population, definition of AP use, adjusted OR,RR or HR with 95% CIs, 
ascertainment of AP use, ascertainment of MI and variables adjusted for in the 
analysis. For studies that applied different models for the calculation of estimate risks, 
results adjusted with more potential confounders were chosen. 
 
Statistical analysis 
 
Review Manager (RevMan) Version 5.3 (The Nordic Cochrane Centre, 2014) 
software was used for data analysis. Adjusted data (adjusted OR,RR or HR with 95% 
CIs) were used for the meta-analysis. Given that the outcome of interest was rare, we 
assumed equivalence of the OR, RR and HR. Studies were combined by using the 
inverse variance method. Pooling was performed in both fixed and random-effect 
models. Heterogeneity was assessed with the I2 index and Cochran’s Q (X2) statistics. 
We considered an I2 value greater than 50% and p≦0.10 as indicative of 
heterogeneity. For the I2 metric, low, moderate, and highvalues were considered to be 
25%, 50%, and 75%, respectively. If the I2 index showed significant heterogeneity 
between the study results, a random-effect model was used. We also performed 
subgroup meta-analyses based on the following: i) type of study design (case-control, 
case-crossover, or cohort study); ii) quality of study methodology;iii) gender; iv) age 
(<50 years, 50-69 years, >70 years); v) dementia or schizophrenia population; vi) time 
window after initiation of APs (≦30 days, ≦60 days or >90 days); vii) presence or 
absence of prior cardiovascular disease (CVD). Sensitivity analyses were employed to 
find potential origins of heterogeneity and to examine the influence of various 
exclusions on the combined OR. The funnel plot approach was used to investigate 
publication bias. 
 
Results 
Study selection 
 
Of 1783 potentially relevant articles identified in the literature search, titles and 
abstracts of 1488 were examined and excluded by the consensus of two authors. In 
cases of discordant exclusions, a third author made the final selection. Thus, 26 
full-text manuscripts were retrieved for detailed evaluation. Of these, 15 were 
excluded for the following reasons: three because they were review articles (Brauer et 
al., 2011; Feinstein, 2002; Ottervanger et al., 1997); one because its psychotropic 
drugs did not include antipsychotic agents (Lapane et al., 1995); three because they 
used risperidone oraripiprazole as the reference group (Citrome et al., 2013; Pasternak 
et al., 2014; Sahlberg et al., 2015); six because they used typical or atypical APs as 
the reference group (Murray-Thomas et al., 2013; Vasilyeva et al., 2013; Huybrechts 
et al., 2012; Kleijer et al., 2012; Mehta et al., 2011; Wang et al., 2009); two because 
they did not use adjusted OR or RR (Barak et al., 2007; Jerrell and McIntyre, 
2007);and one because they included dementia patients only(Pariente et al., 2012).Ten 
studies were thus retained for full data extraction for the meta-analysis. Figure 1 
summarizes the literature search flow. 
 
Study characteristics 
 
Table 1-1, 1-2 and 1-3 summarizes the characteristics of the studies included in the 
meta-analysis. One studies (Brauer et al., 2015; Pariente et al., 2012) analyzed 
twodifferent types of study design:Brauer et al. (2015) used the self-controlled case 
series and case-control study design to investigate the association between MI risk 
and AP use.We found four case-control studies (Brauer et al., 2015; Nakagawa et al., 
2006; Penttinen and Valonen, 1996; Thorogood et al., 1992), two case-crossover 
studies (Wu et al., 2015b; Lin et al., 2014), one case-case time control study (Wang, 
2011), Threecohort studies (Enger et al., 2004; Hwang et al., 2014; Pariente et al., 
2012; Pratt et al., 1996) and oneself-controlled case series(Brauer et al., 2015; 
Pariente et al., 2012). The countries where the studies had been performed were 
Finland, Denmark, UK, Canada, Taiwan, and USA,and the range of study enrolment 
periods was 1980-2012. Eight studies included both males and females, one study was 
male only (Penttinen and Valonen, 1996) and one study female only(Thorogood et al., 
1992). The studies included were similar in terms of ascertainment of AP use and MI, 
mainly reliant on prescription data and diagnostic codes. Three studies (Thorogood et 
al., 1992; Penttinen and Valonen, 1996; Pratt et al., 1996) evaluated exposure to APs 
and the risk of MI by interview and from patients’ records. It should be borne in mind 
that studies conducted before 1996 (Penttinen and Valonen, 1996; Pratt et al., 1996; 
Thorogood et al., 1992)provided information only on typical AP use,and the doses of 
typical agents may have been higher than currently. Table 2 shows the methodological 
quality of included studies. The mean NOS score was 7.2 for the 10 studies (range: 
5-9). 
 
Association between antipsychotic use and the risk of myocardial infarction 
 
The multivariable-adjusted ORs of MI associated with antipsychotic use in individual 
studies and summary estimates are shown in Figure 2. Overall, the use of any 
antipsychotic agent was associated with a significantly increased risk of MI (OR 1.55, 
95% CIs 1.33-1.79),but a high heterogeneity was detected (P<0.10; I2=97%). In a 
subgroup meta-analysis by study design, an increased MI risk with antipsychotic use 
was observed in case-crossover studies (OR 2.41, 95% CIs 2.21-2.64; I2=51%). Table 
3 shows the results of subgroup meta-analyses. In the subgroup meta-analyses 
according to study quality, significant associations of antipsychotic use and increased 
risk of MI were observed among high quality studies (OR 1.42, 95% CIs 1.21-1.66), 
and among low quality studies (OR 3.08, 95% CIs 1.84-5.15). Use of atypical and 
typical APs were associated with significantly increased odds of MI (OR 1.39, 95% 
CIs 1.06-1.82; OR 1.57, 95% CIs 1.29-1.91, respectively). No significant 
differenceswere found in people with use of these agents in both. Increased risk of MI 
was observed in both genders (male: OR 2.83, 95% CIs 2.60-3.08; female: OR 2.26, 
95% CIs 1.36-3.77), and in patients with schizophrenia (OR 2.25, 95% CIs 
1.98-2.55). 
  Higher MI risk was observed in the initial 60 days of exposure to antipsychotic 
agents (≦ 30 days:OR 2.33, 95% CIs 2.02-2.69;≦60 days: OR 2.11, 95% 
CIs1.85-2.40), with ORs decreasing over time (≦ 90 days: OR 1.56, 95% CIs 
1.28-1.91). The risk of MI appeared not to be increased in elderly or in patients with 
or without prior CVD diagnoses. 
 
Sensitivity analyses and publication bias 
 First, specific studies were excluded to further evaluate the reliability and stability of 
our conclusions. We excluded studies from the same database, and studies with two 
study designs. Secondly, the leave-one-out analysis was performed by omitting one 
study in turn. The positive association was not substantially changed in any of these 
analyses. Robust results are displayed in Table 4. Visual inspection of the funnel plot 
showed asymmetry. Thus publication bias was observed. 
 
Discussion 
The aim of this meta-analysis was to assess the risk of MI amongst users of typical 
and atypical APs compared with non-users. Our review included case-control, 
case-crossover, case-case time control, cohort, and self-controlled case series studies. 
Findings suggest the risk of MI is increased generally in AP users compared to 
non-users, with a pooled OR estimate of 1.55 (95% CIs 1.33-1.79). In the subgroup 
meta-analyses, MI risk appears to be greater in case-crossover studies, in male 
genders, in patients with schizophrenia, and during the first 2 months of APs use.  
Our results were consistent with a previous meta-analysis (Yu et al., 2016). 
However, our review identified two additional studies (Wang, 2011; Hwang et al., 
2014) and pooled all risk estimates. Studies conducted before 2006 (Thorogood et al. 
1992, Penttinen and Valonen 1996, Pratt et al. 1996, Enger et al. 2004) were rated as 
low quality based on NOS scores. Higher MI risk was observed among low quality 
studies compared with high quality studies. Higher doses of typical agents were 
prescribed at these earlier years compared to current usual practice, and might cause 
an overestimation on the MI risk. Enger et al. (2004) indicated that AP users in 
patients with schizophrenia had increased risk for MI, compared to controls. The 
higher MI risk observed in APs users with schizophrenia could partly be explained by 
the unhealthy lifestyle (e.g., smoking, lack of exercise and obesity). Some studies (Lin 
et al., 2010; Wu et al., 2015a) have found that people with schizophrenia have a 
higher risk of MI compared to the general population. Besides,  Osborn et al. (2007) 
reported that people with severe mental illness who were not prescribed any APs 
remained at increased risk of coronary heart disease (CHD) than controls, whereas 
those prescribed such agents were at even greater risk. 
Our findings of elevated risk for MI in short term APs users are also consistent with 
those from previous studies (Brauer et al., 2015; Lin et al., 2014; Pariente et al., 2012; 
Yu et al., 2016), where the incidence rate of MI has been found to be higher during the 
first two months of treatment, declining with longer exposure time and potentially 
related to AP tolerance and cross-tolerance (Lin et al., 2014; Yu et al., 2016). Another 
explanation for such possibility might be that the indication for which APs were 
prescribed (e.g., acute psychotic phase in schizophrenia) was associated with state 
dependent cardiovascular risk factors (e.g., agitation), which then being controlled 
(e.g., because of AP treatment) in later months. AP use may merely be a marker for 
the presence of cardiovascular risk factors and not the reason for MI; alternately, APs 
may interact with state-dependent risk factors through unknown mechanisms to 
trigger MI. With regards to the non-significant elevation (Brauer et al., 2015; Pariente 
et al., 2012) in the risk of MI in long-term APs users, since the development of 
atherosclerotic plaque takes a period of years to decades, the mean follow-up time 
from participants in the analyzed cohort studies (approximately 6.5 years with the 
range of 1-13 years)(Enger et al., 2004; Hwang et al., 2014; Pariente et al., 2012; Pratt 
et al., 1996) may be insufficient for AP to meaningfully affect the MI process. 
Therefore, our results tend to reflect relatively short-term effects of AP use. 
 
Mechanism 
 
Mechanisms of MI risk and exposure to APs remains unclear. Since a 
shorter-term relationship for MI risk during the first 2 month of treatment was shown 
in our analysis, this result might indicate other vascular processes (Pariente et al., 
2012) or conduction deficits, as have been proposed as potential causes of sudden 
cardiac death(Wang et al., 2007; Suvisaari et al., 2010). Our results also suggest that 
patients experience an MI early on in the treatment, independent of a history of CVD 
and age, which could point to a triggering effect caused by APs. Similar results were 
found in one previous study (Brauer et al., 2015). Potential pharmacological 
mechanisms might include venous thromboembolism, affinity of APs to D3-dopamine, 
and 5-HT-serotonin receptors as has been discussed in previous literature (Jonsson et 
al., 2012; Lin et al., 2014; O’Brien and Oyebode, 2003). Based on a meta-analysis of 
17observational studies (Barbui et al., 2014), APs were concluded to be associated 
with a50% increased risk of venous thromboembolism. Excessive activation of 
platelets may be involved in MI, stroke, and increased risk of thrombotic 
complications and might be causes of morbidity and mortality in AP users. 
Furthermore, the D3-dopamine receptor has been implicated in the pathogenesis of 
MI in relation to plaque rupture and platelet aggregation(Ricci et al., 2001) in animal 
studies. One study (Lin et al., 2014) of the selected binding of APs to 14 
neurotransmitter receptors revealed only D3-dopamine receptor antagonism to be 
significantly associated with MI risk. The higher MI risk observed in AP users with 
schizophrenia in our study is consistent with the possibility that, in addition to 
unhealthy lifestyle, autonomic nervous system dysfunction triggered by schizophrenia 
may be exacerbated by AP treatment through blockade of peripheral dopamine 
receptors, increasing sympathetic activity (Scigliano and Ronchetti, 2013). Most 
atypical APs are serotonin receptor antagonists, and5-HT-serotonin activity represents 
another possible link with coronary artery diseases. Specifically, activated platelets 
release large amount of serotonin which participates in cardiac remodeling through 
the regulation of endothelial and vascular smooth muscle cells, potentially responsible 
for atherosclerosis (Yabanoglu et al., 2009). Although AP use has a time-dependent 
effect on MI risk, a plethora of recent work from investigators such as Tiihonen et al. 
(2011) have reported that AP treatment is associated with lower mortality (adjusted 
HR 0.45, 95% CIs 0.31–0.67) than no AP use. As APs are effective in treating some 
severe mental illness, the relatively small increased risk of MI is unlikely to alter their 
benefit-risk balance. 
 
Limitation 
 
In drawing conclusions, it is important to bear in mind that non-randomized data 
are susceptible to selection bias and residual confounding. Inadequate control for 
confounders may bias the results in either direction: towards exaggeration or 
underestimation of risk estimates. This study is limited in several ways, which should 
be taken into account when interpreting these data. First, inconsistencies in study 
designs, sample sizes, and participants’  baseline characteristics were found across 
studies. For the case-control studies, we cannot rule out the possibility of recall bias. 
The case-crossover and self-controlled case series studies reduce the possibility of 
between-individual time-invariant confounding (as individuals are their own controls) 
and were more suitable to investigate short-term effects of exposures on acute 
outcomes. Second, each observational study adjusted for different confounding 
factors. Most studies we analyzed  failed to account for one or more of the following 
risk factors for MI: smoking, physical inactivity, obesity, and poor diet. All of which 
might well vary disorder severity, and therefore affect pharmacotherapy received. 
Third, most studies included in this meta-analysis comprised different populations. 
These populations might be different in baseline MI risk. Hence, subgroup analyses 
were conducted based on different study designs and populations to investigate 
potential sources of heterogeneity. Besides, a higher MI risk and lower heterogeneity 
were seen in case-crossover studies and in samples with schizophrenia. Fourth,t he 
use of filled prescriptions to capture exposure information does not allow the 
ascertainment of the participants’ compliance, and disease and outcome measures 
based on diagnostic codes may lack clinical information, such as that on disease 
duration and severity, indication for AP use, and social supports, all of which might be 
related to AP choice. Fifth, this analysis collated individual drugs into typical and 
atypical classes, although effects and adverse reactions may differ between agents 
within a single class. Only one study provided data on MI risk associated with 
individual APs(Lin et al., 2014), finding the highest risk with amisulpiride (OR 5.65, 
95% CIs 2.97-10.76). However, another study conducted by Sahlberg et al. (2015) 
found that the incidence of major adverse cardiovascular events (comprised the first 
occurring nonfatal MI) was higher with use of levomepromazine (RR 3.80, 95% CIs 
3.43-4.21) and haloperidol (RR 1.85, 95% CIs 1.67-2.05) and lower for treatment 
with flupentixol (RR 0.54, 95% CIs 0.45-0.66) and chlorprothixen (RR 076, 95% CIs 
0.61-0.95) compared with risperidone. While the increased MI risk similarly applies 
to typical and atypical APs as previously reported (Huybrechts et al., 2012; Jackson et 
al., 2015; Wang et al., 2009), differences between typical and atypical agents were 
observed in one direct comparison (Vasilyeva et al., 2013) which found higher MI risk 
in people using atypical APs. Inconsistent findings might reveal the heterogeneity in 
receptor-binding profiles among typical and atypical APs and further research on 
individual drugs might still be needed. Finally, dose-response relationships between 
AP use and the risk of MI analyses could not be investigated because of insufficient 
data. 
 
Despite the limitations, it raises awareness of safety issues associated with 
APtreatment. Where no RCTs exit, observational studies may be the only recourse. 
Golder et al. (2011)had reported that there is no difference on average in the risk 
estimate of an intervention’s adverse effects obtained from meta-analyses of RCTs 
and from meta-analyses of observational studies.Our study has strengths in that it 
included a large number of people who were taking APs in a real-life setting, drawn 
from a data resource with near-universal national coverage.Large, nation-wide 
samples provide statistical power advantages. 
 
Conclusion 
The present meta-analysis, consisting of four case-control, two case-crossover, one 
case-case time control, four cohort, and two self-controlled case series studies, 
indicates a significantly increased MI risk in any, atypical and typical AP users 
compared with non-users. Subgroup analyses indicate that male patients, those with 
schizophrenia, and those with AP exposure periods ≦60 days are more likely to 
develop MI. However, caution is needed in interpreting the findings from our results 
because of the high heterogeneity between studies. Findings on MI risk need to be 
viewed in the wider context of lower mortality associated with AP treatment in severe 
mental illness. Instead of suggesting not using APs, the implication would be that 
these high-risk patients group should receive close monitoring before and during AP 
use. More studies are warranted to identify other possible intervening conditions and 
hence potentially vulnerable subpopulations. 
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